Please use this identifier to cite or link to this item:
Title: The Combined Utility of Ex Vivo IFN-γ Release Enzyme-Linked ImmunoSpot Assay and In Vivo Skin Testing in Patients with Antibiotic-Associated Severe Cutaneous Adverse Reactions.
Austin Authors: Trubiano, Jason A ;Strautins, Kaija;Redwood, Alec J;Pavlos, Rebecca;Konvinse, Katherine C;Aung, Ar Kar;Slavin, Monica A;Thursky, Karin A;Grayson, M Lindsay ;Phillips, Elizabeth J
Affiliation: National Centre for Infections in Cancer, National Health and Medical Research Council Centre of Research Excellence, Peter MacCallum Cancer Centre, Department of Oncology, University of Melbourne, Parkville, Victoria, Australia
Departments of Medicine & Pharmacology, Vanderbilt University, Nashville, Tenn
Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia
Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
Department of Infectious Diseases, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia
Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Centre, Nashville, Tenn
Department of General Medicine and Infectious Diseases, Alfred Health and Monash University, Melbourne, Victoria, Australia
Issue Date: Jul-2018 2017-10-31
Publication information: The journal of allergy and clinical immunology. In practice 2018; 6(4): 1287-1296.e1
Abstract: For severe cutaneous adverse reactions (SCARs) associated with multiple antibiotics dosed concurrently, clinical causality is challenging and diagnostic approaches are limited, leading to constricted future antibiotic choices. To examine the combined utility of in vivo and ex vivo diagnostic approaches at assigning drug causality in a cohort of patients with antibiotic-associated (AA)-SCARs. Patients with AA-SCARs were prospectively recruited between April 2015 and February 2017. In vivo testing (patch testing or delayed intradermal testing) was performed to the implicated antibiotic(s) at the highest nonirritating concentration and read at 24 hours through 1 week. Ex vivo testing used patient peripheral blood mononuclear cells (PBMCs) stimulated with a range of pharmacologically relevant concentrations of implicated antibiotics to measure dose-dependent IFN-γ release from CD4+ and CD8+ T cells via an enzyme-linked immunoSpot assay. In 19 patients with AA-SCARs, combined in vivo and ex vivo testing assigned antibiotic causality in 15 (79%) patients. Ten patients (53%) with AA-SCARs were positive on IFN-γ release enzyme-linked immunoSpot assay, with an overall reported sensitivity of 52% (95% CI, 29-76) and specificity of 100% (95% CI, 79-100), with improved sensitivity noted in acute (within 1 day to 6 weeks after SCAR onset) testing (75%) and in patients with higher phenotypic scores (59%). There was increased use of narrow-spectrum beta-lactams and antibiotics from within the implicated class following testing in patients with a positive ex vivo or in vivo test result. We demonstrate the potential utility of combined in vivo and ex vivo testing in patients with AA-SCARs to assign drug causality with high specificity.
DOI: 10.1016/j.jaip.2017.09.004
ORCID: 0000-0002-5111-6367
PubMed URL: 29100867
Type: Journal Article
Subjects: Antibiotic allergy
Delayed hypersensitivity
Stevens-Johnson syndrome
drug reaction with eosinophilia and systemic symptoms
toxic epidermal necrolysis
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Nov 25, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.